Skip to main
XNCR

Xencor (XNCR) Stock Forecast & Price Target

Xencor (XNCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Xencor is Overweight due to its XmAb technology platform, diversified pipeline with multiple potential catalysts, and strong cash position. The potential for positive data updates from Phase 1 expansion data on XmAb819 in ccRCC and updates on other pipeline candidates, combined with the company's focus on unmet medical needs in cancer and autoimmune diseases, contribute to a positive outlook. However, there are inherent clinical and competitive risks as well as the need for additional capital before commercialization of its portfolio.

Bears say

Xencor is facing a number of challenges with its pipeline, as its lead program XmAb819 has been deprioritized in favor of a combination approach with XmAb541 and XmAb808. The company's decision to open substudies in its Phase 1/2 protocol to test XmAb819 in earlier lines of therapy reflects concerns about the drug's effectiveness as a monotherapy, particularly in comparison to newer IO/IO and VEGF treatments. This strategy shift raises doubts about Xencor's ability to successfully commercialize its antibody therapeutics, and can lead to a decline in revenue from collaboration and licensing agreements.

Xencor (XNCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xencor and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xencor (XNCR) Forecast

Analysts have given Xencor (XNCR) a Buy based on their latest research and market trends.

According to 7 analysts, Xencor (XNCR) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xencor (XNCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.